• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » MassDevice Q&A: MassMEDIC president Tom Sommer

MassDevice Q&A: MassMEDIC president Tom Sommer

May 1, 2009 By Brad Perriello

Tom Sommer’s been a major player on the Massachusetts medical device scene for more than a dozen years. As president of the Massachusetts Medical Device Industry Council (MassMEDIC), Sommer runs the nations largest regional medical device council, addressing the needs of more than 400 member companies.

With the council’s May 5 annual conference on the horizon, MassDevice visited Sommer at MassMEDIC’s offices at the Boston Medical Center (PDF) campus to find out what’s on the minds of the device company executives he visits each week, how they’re coping with a down economy and the challenges imposed by the Bay State’s stringent gift ban.

MassDevice: How did you come to MassMEDIC and what was your background before joining the council?

Tom Sommer: I was at the Massachusetts Technology Collaborative for about two years before taking over as the first employee of MassMEDIC. I was assigned a project early on in my tenure there to work with the medical device industry in establishing a new trade association. That was back in 1996.

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/Porter_Michael_100x100.jpg}There was a study that came out of then-Gov. Weld’s council on technology and economic development by Michael Porter, a professor at Harvard Business School. They studied the medical device industry in Massachusetts and came to the conclusion that this was a very under-acknowledged industry sector, but had many positive contributions to the state’s economy. The study included a recommendation that there be a trade association established for the medical device industry. That recommendation went out to the Massachusetts Technology Collaborative and they asked me to get involved in developing plans for such a council. We had our kickoff meeting May 5, 1996.

We’re now the largest regional medical device organization in the United States. We closed last year with 400 dues-paying members. We’ve had great retention; our members have been loyal and helped us grow. We’ve provided a meeting place for medical device companies, suppliers, researchers and investors to come together and network.

MassDevice: There’s a perception that the medical device sector gets short shrift when it comes to public awareness. Why does the industry toil in the shadows of pharma and biotech?

TS: Pharmaceutical, biotech and medical devices are all regulated by the same federal agency, but then the similarities begin to fade. We see different investors, different workers, different timelines for product development and market introduction. It’s really a different outlook.

There definitely is a need by biotech companies and pharmaceutical companies to generate more news stories and coverage of their products as they seek additional investment. Because of the different timeline for product development, manufacturing and market introduction in the medical device sector, we don’t have that same need. We have to attract investment up front, we have to prove our product concepts very early on in order to attract investment. There are different mindsets about PR and media coverage in the three industries. A biotech company has to create buzz about the potential of their product in order to attract investment and continued interest in their product, whereas a medical device startup is focused on the investment first and then product development and manufacturing.

The medical device industry is far more focused on that shorter timeframe and bringing products to market very, very quickly. We don’t have the luxury of time that the pharma and biotech industries have. It’s just the way these products are developed and brought to market.

I don’t think medical device companies have time to worry about their profile. This industry is focused on product approval, product introduction, marketing and sales. It’s the nature of the market, where devices have a shelf life of anywhere from 18 months to two years. They have to be constantly focused on product innovation and enhancement.

MassDevice: What’s your personal favorite among the events MassMEDIC hosts each year?

TS: Our annual investors conference in November is a showcase for early-stage companies, many of which are presenting very novel, very unique technologies.

{IMAGERIGHT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/Sommer_Thomas_200.jpg}What’s fun about it is that these are new companies, people with a lot of enthusiasm and a strong commitment to develop and market their products and grow their companies. They bring that enthusiasm to the conference. There are some terrific success stories. The class of 1999, the group that first presented at the conference, has gone on and raised capital, sold themselves to major companies or done IPOs. For example MicroCHIPS, Confluent Surgical [which was sold to Covidien] and Solx.

And then usually two-and-a-half weeks later, we hold our annual FDA update program, where we bring in some top policy makers from the agency.

That’s an important conference because it gives our members an opportunity to question and challenge and be informed by the people who are making very important decisions affecting their operations. Part of what MassMEDIC was established to do was to give the local medical device community access to the individuals and institutions that are affecting their operations and their companies’ competitive profiles.

MassDevice: What is MedTech Ignite?

TS: MedTech Ignite is a special MassMEDIC project that focuses on supporting select, early-stage companies. We have a screening process in which business plans are reviewed by members of the Ignite advisory board and the director of Ignite, Amy Fredrick. These select companies receive business plan coaching from seasoned and specialized executives in the area the startup is focusing on. For example, we’ll match up an orthopedics entrepreneur with someone who’s been involved in two or three startups in that area.

We have input from venture capital, product development specialists and “serial entrepreneurs” in this space. And Amy has a strong background in technology assessment, having worked for a startup and an established medical device company. We’re looking for companies that have a sound business plan that has apparent challenges; we’re looking for companies that are coachable and we’re also looking for companies that have a proven concept, so that we can take them to the next level by sharpening their business plan and sharpening their presentation to potential investors. We’ve supported about 17 companies since the program was started in February 2007.

MassDevice: What’s the biggest challenge facing the Commonwealth’s medical device industry?

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/Sommer_Thomas_100x100.jpg}TS: One is the so-called gift ban restrictions that are the most stringent, most restrictive regulations of their kind in the United States. That is very difficult to deal with because it came at a time when the state Legislature and the governor supported a life sciences bill to grow the sector here in Massachusetts. In that same time period, we had the Legislature and the governor signing off on this very restrictive piece of legislation that will affect the way medical device companies develop products.

It will affect the way medical device companies here in Massachusetts work with the medical community. We’ll need to go elsewhere in order to effectively work with them. It will also affect the way companies train potential and current customers on using their products. And it will provide competitors with a view into the product development operations of Massachusetts medical device companies, by reviewing the payments made to healthcare practitioners and the purpose of those payments.

It puts us at a very distinct disadvantage. We’re very disappointed in the final outcome. We don’t believe that policymakers fully understand the process required of medical device companies to develop new and innovative products.

In addition to all that, the timing of these regulations was just awful. Given the current economic climate, to put additional pressures on the device and biotech industries to comply with these regulations — it’s bad public policy and it will have a negative effect on the future growth of the device industry here.

The impact is not going to be immediate, but it’s going to be long-term. We’re confounded with, on the one hand, the Massachusetts state government coming forward with this life science initiative and, on the other hand, there is this very restrictive measure passed.

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/Patrick_Deval_100x100.jpg}The governor of Massachusetts [Deval Patrick] came to our annual conference last year and said that he hopes that in 10 years we’d look back on his administration as one that actually understood and got it, understood the problems and the challenges of the medical device industry. He walked out to a standing ovation.

Less than 90 days later he signs this bill into law.

MassDevice: What’s your membership’s take on the possibility of a national, single-payer healthcare system?

TS: Reimbursement and purchasing obviously are two factors that have not been adequately addressed for us to take a position on a universal, one-payer system. The universal system in Massachusetts is only a year-and-a-half old and I think it’s still too early to tell how things are working out. The economic downturn has skewed all the numbers, so I don’t think we can get a really good analysis of this yet. A lot’s going to depend on the blueprint the president and the Congress agree on and how that will affect medical device sales.

There’s some concern as to what the new healthcare policy will be and how that will affect our members’ operations. They’re very anxious to see how some of these new policies will impact their operations. They’re looking to see what healthcare reform brings when it’s formally introduced. There’s lots of interest and concern as to what changes the FDA will bring, with a new commissioner and a new deputy commissioner with public health backgrounds. They don’t necessarily have a record of involvement with industry.

There’s also a lot of interest in what Congress will do. There are a number of invasive devices that were approved as of 1976 which will require more device approvals to be accompanied by clinical trial data. All of this is in play.

MassDevice: Apart from the regulatory burdens, the economy is obviously a huge issue for all businesses. How is the recession affecting the local medical device sector?

TS: There are a number of factors that have come into play in the last six to eight months. Hospitals are in very bad shape. Revenues are down and they’re putting off decisions to purchase equipment and devices where they can. We’re seeing a real falloff in the purchase of capital equipment — electro-medical equipment, MRIs, CAT scans, ultrasound machines — those purchases are being put off for the time being.

And any company selling devices used in elective or non-reimbursable procedures is definitely feeling it. Patients are putting off a variety of cosmetic procedures.

The other sector that’s having some difficulty are early-stage companies in the middle rounds of financing. Investors have an easier time supporting companies that have been around for a while and are looking for that final round of venture funding, and they also don’t have a problem investing at the earlier stage, because the new technology is exciting. It’s the new companies that are in the middle that are having difficulty attracting further venture investment.

But companies are holding their own. Certainly it’s not as good as last year, but they’re operating and generally satisfied with their performance — especially when they look at other industry sectors and see what’s happening there.

MassDevice: How does a typical day for Tom Sommer shake out?

TS: I travel throughout the state frequently; I’m on the road a couple days a week, visiting members at their facilities and also meeting with folks involved in state government policy and attending informational sessions. I try to interact as much as I can with our members. When I’m not on the road, I’m usually here nice and early working on several projects.

MassDevice: What’s the most mind-blowing medical device you’ve seen come out of the Bay State?

TS: We don’t have the “wow factor” that biotech and pharma have, because we’re not necessarily curing people. These are devices usually used for treatment or diagnosis. They don’t have the spectacular “wow” that you get with a wonder drug that cures a disease. But still, there’s a lot of amazing technology.

I’m amazed at what’s happening in orthopedics, for example what ConforMIS is doing in bone repair and joint replacement is absolutely fantastic. They take an imprint of your joint structure if you will and that’s then removed and there’s basically a replacement made using that impression.

MassDevice: What else is on the council’s horizon?

TS: We’ve got a small state grant to identify the workforce training gaps in the medical device industry and develop a curriculum for worker training that would address some of those shortfalls. For instance, if you have an opportunity to hire a terrific mechanical engineer but he or she lacks experience in the industry, in order for them to develop their medical device career they need to be schooled in FDA protocol and reimbursement protocol, because those two areas affect just about every aspect of medical device development.

Filed Under: Uncategorized Tagged With: Gift Bans, MassDevice Q&A

In case you missed it

  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
  • Nasdaq grants Titan Medical 180-day extension to regain compliance
  • Aerin Medical reports positive 4-year results for VivAer treatment
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
  • How medical device companies are responding to abortion bans
  • Clarius partners with ImaCor on handheld hemodynamic ultrasound tech
  • Withings appoints Elizabeth Coleon as chief marketing officer
  • Visby Medical raises $135M in expanded Series E
  • Boston Scientific to build new plant outside Atlanta
  • NovaXS unveils prototype for smart, needle-free drug delivery device
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
  • SpineX enrolls first patient in spinal neuromodulation technology trial
  • GE Healthcare’s Carescape ventilator battery recall is Class I
  • Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
  • Advanced NanoTherapies closes $7.2M Series A for drug-coated balloon
  • Centerline Biomedical raises $33M Series B

RSS From Medical Design & Outsourcing

  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]
  • Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
    Cardinal Health (NYSE: CAH) today started air delivery of pharmaceutical products and medical supplies via Zipline drone in North Carolina. San Francisco-based Zipline won FAA Part 135 air carrier certification for the long-range flights earlier this month. The company flew its first commercial deliveries on June 22 with an initial 16-nautical-mile flight. The flights starting… […]
  • Boston Centerless opens manufacturing plant in Indiana
    Boston Centerless announced today that it opened a second manufacturing plant in Fort Wayne, Indiana. Woburn, Massachusetts-based Boston Centerless said in a news release that the latest expansion for the supplier of precision ground bar materials for close tolerance CNC Swiss machining applications represents continued robust growth in key market segments in the Midwest and… […]
  • Dymax strikes new partnership with Quantum Systems
    Rapid curing materials and equipment manufacturer Dymax today announced a new sales partnership with Quantum Systems. Torrington, Connecticut-based Dymax said in a news release that Quantum, with its offices in Arizona as well as Sonora and Baja, Mexico, will focus its efforts on promoting and supporting the sales of Dymax light-curing solutions to the medical,… […]
  • Researchers develop wearable robotic exomuscle system
    ETH Zurich researchers have redefined the muscle shirt. Marie Georgarakis, a former doctoral student at ETH Zurich’s Sensory Motor Systems Lab, is the creator of the Myoshirt, a wearable, textile robotic device that helps users lift their arms and reach. A motorized cable works like an artificial tendon, directed by sensors and an algorithm to… […]
  • They said it at DeviceTalks Boston
    Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead. Here are some of the most quotable insights from panelists and speakers at our live event. And make sure to save the date — and save your seat… […]
  • Summer health technology program brings diverse group of interns to Silicon Valley
    Diversity by Doing HealthTech (DxD) is holding a Summer Innovation and Exploration Series for college student interns from underrepresented groups. The series is on its second day today at Fogarty Innovation and Stanford Byers Center for Biodesign — the two organizations that jointly formed and support DxD. The event debuted last year in an online… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS